Jack Emery and his team at the Hudson Institute in Clayton, Australia, were staring at a ghostly green glow under the microscope—tiny extracellular vesicles from Helicobacter pylori, each carrying a hidden payload of Tipα, a protein long suspected of driving stomach cancer. What they saw rewrote the story of one of the world’s most widespread infections. For decades, scientists knew H. pylori caused 90% of non-cardia stomach cancers and infected nearly half the planet—4.4 billion people—but the mechanics of how it turned chronic infection into cancer remained murky. Now, Emery and Professor Richard Ferrero have uncovered a crucial missing link: the bacterium doesn’t just secrete the Tipα protein into the stomach lining. It packages it into microscopic delivery pods—extracellular vesicles—that ferry it directly into the nucleus of human stomach cells.
This discovery, published in the Journal of Extracellular Vesicles, flips previous assumptions on their head. Earlier studies suggested Tipα triggered inflammation by boosting TNF, a key immune signal. But those experiments used free-floating Tipα, not the vesicle-encased form the bacterium actually deploys. The Hudson team found that when Tipα arrives via vesicles, it does the opposite—it suppresses TNF and IL-8, quieting the immune response. That stealth move may be precisely how H. pylori lingers undetected for decades, slowly setting the stage for cancer. “We found that when Tipα is delivered via EVs, it can actually temper the inflammatory response,” Emery said. “It reduces production of TNF and IL-8, which may help H. pylori persist in the stomach for decades.”
The implications are profound. Stomach cancer has a five-year survival rate of just 40%, largely because it’s diagnosed so late. By revealing how H. pylori manipulates host cells at the molecular level, this research opens new paths for early detection and targeted therapies. If clinicians can measure Tipα levels in vesicles—or block their entry into cells—they might intercept the disease long before tumors form. The team also found that different H. pylori strains package varying amounts of Tipα, raising the possibility that some strains are more dangerous than others—a question that could reshape screening and treatment.
This work cements the Hudson Institute’s role as a global leader in H. pylori research. For Emery and Ferrero, the journey is just beginning. “Understanding how H. pylori manipulates stomach cells is essential if we want to understand and prevent cancer,” Emery said. With billions still infected worldwide, the quiet delivery of a single protein in a tiny vesicle may hold the key to turning a deadly, persistent infection into a preventable one.